Valuation: Orion Oyj

Capitalization 9.57B 11.13B 8.75B 8.35B 15.31B 1,068B 15.57B 105B 40.64B 507B 41.76B 40.86B 1,766B P/E ratio 2026 *
17.6x
P/E ratio 2027 * 15.3x
Enterprise value 9.49B 11.03B 8.68B 8.28B 15.18B 1,058B 15.43B 104B 40.29B 502B 41.4B 40.51B 1,750B EV / Sales 2026 *
4.59x
EV / Sales 2027 * 4.02x
Free-Float
90.38%
Yield 2026 *
2.78%
Yield 2027 * 3.02%
1 day+1.04%
1 week-0.73%
Current month-0.95%
1 month-7.60%
3 months-0.15%
6 months+13.42%
Current year+6.91%
1 week 65.1
Extreme 65.1
69
1 month 65.1
Extreme 65.1
75.3
Current year 62.7
Extreme 62.7
75.3
1 year 56.5
Extreme 56.5
75.3
3 years 31.86
Extreme 31.86
75.3
5 years 31.86
Extreme 31.86
75.3
10 years 22.57
Extreme 22.57
75.3
Manager TitleAgeSince
Chief Executive Officer 59 2022-10-31
Director of Finance/CFO 50 2024-04-30
Chief Operating Officer 46 2021-12-31
Director TitleAgeSince
Director/Board Member 63 2017-03-21
Director/Board Member 65 2017-03-21
Director/Board Member 66 2020-05-05
Change 5d. change 1-year change 3-years change Capi.($)
+1.04%-0.73%+18.97%+65.77% 11.13B
-0.00%+5.95%+32.68%+130.14% 896B
-1.77%+2.44%+49.81%+42.28% 546B
-0.18%+4.39%+14.33%+46.83% 372B
+0.88%+2.38%+24.30%+14.35% 328B
-0.10%+2.93%+27.56%+26.14% 283B
-0.79%+2.16%+31.97%+12.94% 282B
-1.79%0.00%+46.44%-4.05% 275B
+0.91%+3.07%-29.86%-47.76% 206B
-2.22%-1.62%+19.79%+43.19% 176B
Average -0.40%+2.13%+23.60%+32.98% 337.45B
Weighted average by Cap. -0.50%+3.37%+28.71%+50.44%

Financials

2026 *2027 *
Net sales 2.07B 2.4B 1.89B 1.8B 3.3B 230B 3.36B 22.67B 8.77B 109B 9.01B 8.82B 381B 2.31B 2.68B 2.11B 2.01B 3.69B 257B 3.75B 25.32B 9.8B 122B 10.07B 9.85B 426B
Net income 543M 631M 497M 474M 869M 60.56B 883M 5.96B 2.31B 28.75B 2.37B 2.32B 100B 628M 730M 574M 548M 1B 70.01B 1.02B 6.89B 2.67B 33.23B 2.74B 2.68B 116B
Net Debt -82.12M -95.43M -75.08M -71.64M -131M -9.16B -134M -901M -349M -4.35B -358M -350M -15.14B -308M -358M -281M -268M -492M -34.31B -500M -3.38B -1.31B -16.29B -1.34B -1.31B -56.75B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,132
Date Price Change Volume
26-05-15 68.05 +1.04% 139,921
26-05-13 67.35 0.00% 140,303
26-05-12 67.35 +0.22% 115,401
26-05-11 67.20 -1.97% 178,310
26-05-08 68.55 -1.44% 97,067
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
68.05EUR
Average target price
74.17EUR
Spread / Average Target
+8.99%

Quarterly revenue - Rate of surprise